Zobrazeno 1 - 10
of 14
pro vyhledávání: '"Despoina Mparmparoussi"'
Autor:
Maria Gkotzamanidou, Marina Iakovaki, Maria Gavriatopoulou, Efstathios Kastritis, E. Terpos, Charis Matsouka, Maria Roussou, Meletios A. Dimopoulos, Eleni Efstathiou, Magdalini Migkou, Dimitrios Christoulas, Despoina Mparmparoussi
Publikováno v:
Leukemia. 24:1769-1778
We prospectively studied the impact of several cytogenetic abnormalities (CAs) in patients with relapsed/refractory myeloma who received lenalidomide and dexamethasone (RD) with or without the addition of bortezomib (V). On the basis of the presence
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::16d082e9d3c8040d51f280e66ef86176
https://doi.org/10.1038/leu.2010.175
https://doi.org/10.1038/leu.2010.175
Autor:
Despoina Mparmparoussi, Dimitrios C. Ziogas, Meletios A. Dimopoulos, Evangelos Eleutherakis-Papaiakovou, Maria Gavriatopoulou, E. Terpos, Dimitra Bacharaki, Ioannis Panagiotidis, Stavroula Giannouli, Magdalini Migkou, Charis Matsouka, Smaragdi Marinaki, Maria Roussou, E Kastritis, Erasmia Psimenou, N. Kanellias, Despina Fotiou
Publikováno v:
Blood Cancer Journal
About 50% of newly diagnosed mutilple myeloma (MM) patients (NDMM) have some degree of renal impairment (RI) at presentation, up to 20% have severe acute kidney injury (AKI) and ~1–5% may require extrarenal dialysis, whereas severe RI is associated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0598675522916bd6faebe6b5402cf369
http://europepmc.org/articles/PMC5520396
http://europepmc.org/articles/PMC5520396
Autor:
Maria Gavriatopoulou, Meletios A. Dimopoulos, Efstathios Kastritis, Evangelos Eleutherakis-Papaiakovou, Evangelos Terpos, Despoina Mparmparoussi, Dimitra Bacharaki, Dimitrios C. Ziogas, Ioannis Panagiotidis, Despina Fotiou, Maria Roussou, Stavroula Giannouli, Nikolaos Kanellias, Charis Matsouka, John Boletis, Erasmia Psimenou, Magdalini Migkou
Publikováno v:
Blood. 128:4492-4492
Renal failure (RF) is a common severe complication of symptomatic myeloma and may be severe enough to require extrarenal dialysis in approximately 1-5% of newly diagnosed patients. Severe RF is associated with high risk of early death and increased m
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8d1fef7fea26efe2f656231edfbaef38
https://doi.org/10.1182/blood.v128.22.4492.4492
https://doi.org/10.1182/blood.v128.22.4492.4492
Autor:
Sossana Delimpasi, Nikolaos Kanellias, Panagiotis Tsirigotis, Charis Matsouka, Ioannis Panagiotidis, Stavroula Giannouli, Meletios A. Dimopoulos, Evangelos Eleutherakis-Papaiakovou, Kostas Konstantopoulos, Magdalini Migkou, Evangelos Terpos, Despina Fotiou, Efstathios Kastritis, Maria Roussou, Despoina Mparmparoussi, Dimitrios C. Ziogas, Maria Gavriatopoulou, Christos Poziopoulos
Publikováno v:
Blood. 128:3310-3310
Pomalidomide with low dose dexamethasone (Pd) is a standard treatment for patients who have failed both lenalidomide (Len) & bortezomib (Bor). Phase III studies showed that Pd is active irrespective of the number of prior therapies and whether Len or
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::2a607d025b1b8133a656bb626fca3984
https://doi.org/10.1182/blood.v128.22.3310.3310
https://doi.org/10.1182/blood.v128.22.3310.3310
Autor:
E. Terpos, Despoina Mparmparoussi, Maria Roussou, M Spyropoulou-Vlachou, Meletios A. Dimopoulos, Maria Gkotzamanidou, Charis Matsouka, Nikitas Nikitas, Erasmia Psimenou, Efstathios Kastritis
Publikováno v:
Leukemia. 27(2)
The role of thalidomide, bortezomib and lenalidomide in multiple myeloma patients presenting with renal impairment was evaluated in 133 consecutive newly diagnosed patients who were treated with a novel agent-based regimen. A significant improvement
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c9bb8e855c566550800b6493a1e20b9
https://pubmed.ncbi.nlm.nih.gov/22763386
https://pubmed.ncbi.nlm.nih.gov/22763386
Autor:
Maria Roussou, Despoina Mparmparoussi, Charis Matsouka, Maria Gavriatopoulou, Efstathios Kastritis, Evangelos Terpos, Dimitrios Christoulas, Eleni Efstathiou, Irini Grapsa, Erasmia Psimenou, Magdalini Migkou, Meletios A. Dimopoulos
Publikováno v:
European journal of haematology. 85(1)
Objectives: Lenalidomide and dexamethasone (LenDex) is an active regimen for relapsed/refractory multiple myeloma (MM). However, there is limited data for the effect of LenDex on renal impairment (RI) and on renal reversibility. Patients & Methods: F
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6975394dd66e0aedab9861b1aafeac7c
https://pubmed.ncbi.nlm.nih.gov/20192988
https://pubmed.ncbi.nlm.nih.gov/20192988
Autor:
Evangelos Kostis, Zafiris Kartasis, Despoina Kalapanida, Dimitra Gika, Sofoklis Kontogiannis, Athanasios Zomas, Maria Gavriatopoulou, Evangelos Terpos, Charis Matsouka, Maria Roussou, Meletios A. Dimopoulos, Evangelos Eleutherakis-Papaiakovou, Efstathios Kastritis, Despoina Mparmparoussi, Kostas Konstantopoulos
Publikováno v:
Blood. 124:4738-4738
Multiple Myeloma (MM) is a disease of the elderly and due to the aging population an increasing number of patients are diagnosed at the age ≥80 year. The management of these octogenarians is challenging due to their frailty as a result of co-morbid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b304ff5eb56e1b3dfe7b6e2558f05ff7
https://doi.org/10.1182/blood.v124.21.4738.4738
https://doi.org/10.1182/blood.v124.21.4738.4738
Autor:
Kostas Konstantopoulos, Maria Roussou, Meletios A. Dimopoulos, Evangelos Eleutherakis-Papaiakovou, Despoina Kalapanida, Charis Matsouka, Ioannis Boletis, Efstathios Kastritis, Theodoros P. Vassilakopoulos, Dimitra Gika, Marios Bakogeorgos, Erasmia Psimenou, Despoina Mparmparoussi, Maria Gavriatopoulou, Evangelos Terpos
Publikováno v:
Blood. 124:4769-4769
Renal impairment (RI) is a frequent complication of multiple myeloma (MM) and is associated with significant morbidity and risk of early death. Patients with severe RI (eGFR 60 ml/min/1.73 m2, renal partial response (PRrenal) as an increase of eGFR f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::7c99b8b9e19cc036326879682c2bc5c2
https://doi.org/10.1182/blood.v124.21.4769.4769
https://doi.org/10.1182/blood.v124.21.4769.4769
Autor:
Maria Roussou, Evangelos Terpos, Despoina Kalapanida, Meletios A. Dimopoulos, Thaleia Meletiou, Evangelos Eleutherakis-Papaiakovou, Marios Bakogeorgos, Spyros Orfanopoulos, Dimitra Gika, Efstathios Kastritis, Charis Matsouka, Vasiliki Bampali, Despoina Mparmparoussi, Maria Gavriatopoulou
Publikováno v:
Blood. 124:3464-3464
The presence of certain cytogenetic abnormalities on plasma cells is considered as one of the most important prognostic factors for patients with newly diagnosed symptomatic myeloma. Non-hyperdiploid metaphase karyotype, the presence of del 17p, t(4;
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8f2e68f9ea567843d62a6d5f91c25e4f
https://doi.org/10.1182/blood.v124.21.3464.3464
https://doi.org/10.1182/blood.v124.21.3464.3464